Use of oral enzymes in
multiple sclerosis patients.
Mertin J.1, Stauder G., and the ESEMS
working group. Use of oral enzymes in multiple sclerosis patients.
Inter. Journal of Tissue
Reactions 1997, Vol. XIX , No.1/2, pp 95
Abstract: In 1986, a first report on a cohort of 300 multiple
sclerosis (MS) patients treated with hydrolytic enzymes describes
stabilizing of the disease and reduction of the relapse rate. These
findings have been supported by case reports and by subjective
patient reports. Soon it became clear that a stepwise approach was
necessary, in order to prove whether oral enzymes are effective and
safe in MS. As first step an open multicentric study was performed.
An evaluation of the data showed hydrolytic enzymes to stabilize the
neurological impairment and to improve activities of daily living.
Now a randomized, prospective, double-blind, placebo-controlled
study according to the European GCP-guidelines is going on. 300
patients from 23 European centres are included to randomly receive
Phlogenzym or placebo in a daily dose of 3 tablets b.i.d. or 2
tablets t.i.d. over a period of 2 years. Progression rate, relapse
rate, neurological signs and symptoms (incl. MRI), emotional status
and unwanted side effects are main endpoints.
Some have already finished the treatment period. Results of that
study will be available in early 1999. In case the enzymes prove to
be superior over placebo a safe and inexpensive therapy in the
management of MS would be available.